Skip to main content
. 2020 Feb 27;7(3):ofaa066. doi: 10.1093/ofid/ofaa066

Table 2.

Clinical Characteristicsa

Characteristics VBC-CAP (n = 57) V-CAP (n = 98) B-CAP (n = 968) P Value
Days from onset of symptoms to admission (median, IQR) 4 (3–7) 5 (3–7) 4 (2–7) .017
Clinical Manifestations
 Axillary temperature ≥38ºC 31 (54.4%) 54 (55.1%) 757 (43.0%) .017
 Previous URTI 15 (26.3%) 35 (35.7%) 294 (30.5%) .766
 Chills 21 (36.8%) 29 (29.6%) 368 (38.1%) .249
 Diarrhea/vomiting 7 (12.3%) 25 (25.5%) 202 (20.9%) .148
 Cough 56 (98.2%) 95 (96.9%) 833 (86.1%) <.001
 Purulent sputum 36 (63.20%) 34 (37%) 435 (46.7%) .008
 Chest pain 15 (26.3%) 15 (15.3%) 351 (36.3%) <.001
 Dyspnea 40 (70.20%) 73 (74.5%) 660 (68.2%) .427
 Headache 7 (12.30%) 17 (17.3%) 136 (14.0%) .612
 Myalgia 29 (50.9%) 54 (55.10%) 176 (18.2%) <.001
 Confusion 3 (5.3%) 5 (5.1%) 170 (17.6%) <.001
 Septic shock at presentation 6 (10.5%) 7 (12.1%) 63 (9.1%) .028
Radiological Findings
 Multilobular involvement 3 (5.3%) 7 (7.1%) 222 (12.6%) .047
 Bilateral pulmonary infiltrates 20 (35.1%) 31 (31.6%) 363 (20.6%) <.001
 Interstitial pattern 5 (8.8%) 32 (32.7%) 31 (1.8%) <.001
 Unilobular pulmonary infiltrates 28 (49%) 28 (28.6%) 1159 (65.8%) <.001
 Pleural effusion 8 (14%) 7 (7.2%) 277 (15.7%) .073
Laboratory Findings
 Respiratory insufficiency 38 (67.9%) 58 (63.73%) 504 (59.7%) .163
 Leukocytes (×109/L) 9.6 (5.55–14.95) 7.0 (4.7–10.92) 12.8 (9.15–18.10) <.001
 Neutrophils (×109/L) 83.6% (78.75–88.25%) 81.55% (72.55–86.97) 84% (77.4%–88%) .018
 SAPS ≥6 11 (19.3%) 15 (15.3%) 306 (31.6%) .001
 PSI score ≥4 23 (40.4%) 40 (40.8%) 651 (67.3%) <.001
 CURB-65 score ≥2 25 (43.9%) 42 (42.9%) 675 (69.7%) <.001

Abbreviations: B-CAP, bacterial community-acquired pneumonia; IQR, interquartile range; PSI, pneumonia severity index for adult; SAPS, simplified acute physiology score; URTI, upper respiratory tract infection; V-CAP, viral CAP; VBC-CAP, viral and bacterial coinfection CAP.

aProportions were calculated as percentages of patients with available data.